| Literature DB >> 29671797 |
Takahiro Fujioka1, Anh T Hoang2, Tetsuji Okuda3, Haruka Takeuchi4, Hiroaki Tanaka5, Long D Nghiem6.
Abstract
A new membrane fouling control technique using ozonated water flushing was evaluated for direct nanofiltration (NF) of secondary wastewater effluent using a ceramic NF membrane. Experiments were conducted at a permeate flux of 44 L/m²h to evaluate the ozonated water flushing technique for fouling mitigation. Surface flushing with clean water did not effectively remove foulants from the NF membrane. In contrast, surface flushing with ozonated water (4 mg/L dissolved ozone) could effectively remove most foulants to restore the membrane permeability. This surface flushing technique using ozonated water was able to limit the progression of fouling to 35% in transmembrane pressure increase over five filtration cycles. Results from this study also heighten the need for further development of ceramic NF membrane to ensure adequate removal of pharmaceuticals and personal care products (PPCPs) for water recycling applications. The ceramic NF membrane used in this study showed approximately 40% TOC rejection, and the rejection of PPCPs was generally low and highly variable. It is expected that the fouling mitigation technique developed here is even more important for ceramic NF membranes with smaller pore size and thus better PPCP rejection.Entities:
Keywords: ceramic membrane; membrane fouling; nanofiltration; ozone; water recycling
Mesh:
Substances:
Year: 2018 PMID: 29671797 PMCID: PMC5923841 DOI: 10.3390/ijerph15040799
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Physicochemical characteristics of the selected pharmaceuticals and personal care products (PPCPs) (data from ChemAxon (https://www.chemaxon.com/)).
| Compound | MW [Da] | Log | pKa | Ionisation at pH 6.5 [%] | Suppliers | ||
|---|---|---|---|---|---|---|---|
| Neutral | Hydrophilic | Acetaminophen | 151.17 | 0.91 | 9.46 | 0 | Wako |
| Theophylline | 180.17 | −0.79 | 7.82, −0.78 | 5 | Wako | ||
| Antipyrine | 188.23 | 1.22 | 0.49 | 0 | Wako | ||
| Caffeine | 194.19 | −0.55 | −1.16 | 0 | Wako | ||
| Primidone | 218.26 | 1.12 | 11.5 | 0 | Wako | ||
| Cyclophosphamide | 261.08 | 0.10 | 13.43, 0.08 | 0 | Wako | ||
| Sulfathiazole | 255.31 | 0.86 | 6.93, 2.04 | 27 | Wako | ||
| Sulfamerazine | 264.30 | 0.41 | 6.99, 2 | 24 | Wako | ||
| Sulfadimidine | 278.33 | 0.54 | 6.99, 2 | 24 | Wako | ||
| Sulfamonomethoxine | 280.30 | 0.66 | 7.15, 2.63 | 18 | Wako | ||
| Sulfadimethoxine | 310.33 | 1.14 | 6.91, 1.95 | 28 | Wako | ||
| Thiamphenicol | 356.21 | −0.22 | 8.75 | 1 | Wako | ||
| Dipyridamole | 504.64 | 0.03 | 3.54, 14.97 | 0 | Wako | ||
| Hydrophobic | Isopropylantipyrine | 230.31 | 2.35 | 0.87 | 0 | Wako | |
| Carbamazepine | 236.27 | 2.77 | 15.96 | 0 | Wako | ||
| Griseofulvin | 352.77 | 2.17 | - | 0 | MP | ||
| Charged | + | Ethenzamide | 165.19 | 1.53 | 6.2, 7.9 | 51 | Wako |
| Salbutamol | 239.32 | −2.01 | 9.4, 10.12 | 100 | Wako | ||
| Propranolol | 259.35 | −0.32 | 9.67, 14.09 | 100 | Wako | ||
| Atenolol | 266.34 | −2.48 | 9.68, 14.07 | 100 | Wako | ||
| Trimethoprim | 290.32 | 0.60 | 7.16 | 82 | Wako | ||
| Disopyramide | 339.48 | 0.11 | 10.42 | 100 | Wako | ||
| Sulpiride | 341.43 | −1.55 | 8.39, 10.24 | 99 | Wako | ||
| Pirenzepine | 351.41 | 0.19 | 7.2, 14.78 | 82 | Wako | ||
| Diltiazem | 414.52 | 1.05 | 8.18. 12.86 | 98 | Wako | ||
| Tiamulin | 493.75 | 1.61 | 9.51, 14.43 | 100 | Wako | ||
| Clarithromycin | 747.97 | 1.36 | 8.38, 12.46 | 99 | Wako | ||
| Azithromycin | 749.00 | −2.89 | 9.57, 12.43 | 100 | LKT | ||
| Roxithromycin | 837.06 | 0.47 | 9.08, 12.45 | 100 | Wako | ||
| Tylosin | 916.11 | 1.54 | 7.2, 12.45 | 83 | Wako | ||
| − | Clofibric acid | 214.65 | −0.08 | 3.37 | 100 | Alfa A. | |
| Naproxen | 230.26 | 0.70 | 4.19 | 100 | Wako | ||
| Nalidixic acid | 232.24 | 0.33 | 4.66, 5.77 | 84 | Wako | ||
| Mefenamic acid | 241.29 | 2.83 | 3.89, −1.58 | 100 | Wako | ||
| Fenoprofen | 242.27 | 1.15 | 3.96 | 100 | LKT | ||
| Sulfapyridine | 249.29 | 0.64 | 6.24, 2.13 | 65 | Wako | ||
| Sulfamethoxazole | 253.28 | 0.38 | 6.16, 1.97 | 69 | Wako | ||
| Ketoprofen | 254.29 | 1.05 | 3.88 | 100 | Wako | ||
| Diclofenac | 296.15 | 1.79 | 4.00 | 100 | Wako | ||
| Furosemide | 330.74 | −0.48 | 4.25, −1.52 | 99 | Wako | ||
| Indometacin | 357.79 | 0.88 | 3.79 | 100 | Wako | ||
| Levofloxacin | 361.37 | 0.27 | 5.29, 6.16 | 67 | LKT | ||
| Bezafibrate | 361.82 | 1.37 | 3.83, −0.84 | 100 | LKT | ||
| +/− | Norfloxacin | 319.34 | −0.98 | 5.58, 8.68 | 89 | Wako | |
| Ciprofloxacin | 331.35 | −0.87 | 5.56, 8.68 | 89 | LKT | ||
| Enrofloxacin | 359.40 | 0.96 | 5.52, 6.66 | 96 | ICN | ||
| Tetracycline | 444.44 | −3.50 | 8.19, 2.92 | 97 | Wako | ||
| Chlortetracycline | 478.88 | −2.96 | 2.65, 8.55 | 98 | Wako | ||
Figure 1(a) Photo of the nanofiltration (NF) ceramic membrane and (b) schematic diagram of the cross-flow NF filtration system.
Figure 2Transmembrane pressure (TMP) during NF filtration of the secondary wastewater effluent at permeate flux of 11 and 44 L/m2h (feed water temperature = 20 °C, cross-flow velocity = 0.43 m/s).
Figure 3Rejection of PPCPs by the ceramic NF membrane during NF filtration of the secondary wastewater effluent. Values and error bars are the average and standard deviation of two replicate samples.
Figure 4Rejection of (a) neutral and (b) charged PPCPs by the ceramic NF membrane as a function of their molecular weight.
Figure 5Normalised TMP (TMP/TMP0) during NF filtration of the secondary wastewater effluent and surface flushing with (a) ozone-free and (b) ozonated water (permeate flux = 44 L/m2h, feed and flushing water temperature = 20 °C, cross-flow velocity = 0.43 m/s, flushing time = 5 min).
Figure 6Differential TMP (dP/dt) during NF filtration of the secondary wastewater effluent and surface flushing with (a) ozone-free and (b) ozonated water.
Figure 7TMP at the beginning of each filtration cycle (permeate flux = 44 L/m2h, feed water temperature = 20 °C, cross-flow velocity = 0.43 m/s).